Raymond James & Associates Agios Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
244Shares Held
59.9MCall Options Held
270KPut Options Held
332K-
Farallon Capital Management LLC San Francisco, CA5.67MShares$201 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$200 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$172 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.52MShares$125 Million2.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.42MShares$86 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $1.94B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...